The combination of the HDC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo

In this study, we investigated the synergistic potential of these two drugs in combination against TNBC. Our results suggested that the combination of these two drugs could enhance the inhibitory effect on cancer cell proliferation, resulting in alterations in cell mitotic phase, and suppression of cancer cell stemness. Moreover, our in vivo study unveiled that when SAHA was combined with DOX, it not only exhibited an inhibitory effect on tumor metastasis but also played a role in regulating the immune microenvironment within tumors. Overall, the combination of DOX and SAHA presents a promising avenue for innovative combination chemotherapy in the context of TNBC.PMID:37716547 | DOI:10.1016/j.phrs.2023.106926
Source: Cell Research - Category: Cytology Authors: Source Type: research